Shared risk-reward agreement to focus on early stage discovery in multiple therapeutic areas

Jubilant Biosys Ltd., Bangalore, the India based subsidiary of Jubilant Organosys Ltd,New Delhi, India and Amgen Inc, Thousand Oaks, California, the largest US based Biotech company, today announced a drug discovery partnership under which Amgen and Jubilant will collaborate to develop a portfolio of novel drugs in new target areas of interest across multiple therapeutic areas. Under the agreement, Jubilant will develop early preclinical candidates emanating from Amgen's early discovery efforts for an initial term of three years. Amgen will have responsibility for the subsequent pre-clinical and clinical development and commercialization. Amgen will retain / own the drugs developed under the collaboration with worldwide commercialization rights. Jubilant Biosys will partner in early-preclinical development effort from its state of the art Jubilant Research Centre - Bangalore, while Amgen will pursue later stage pre-clinical and clinical development and commercialization of the drugs in global markets.The financial terms include a combination of research funding and success-based milestones paid to Jubilant during pre-clinical and clinical development for multiple projects undertaken by the collaboration. The total financial Milestone value is subject to successful development and commercialization of the portfolio of novel drugs.

Commenting on the development, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director of Jubilant Organosys said: "We are very pleased to expand our relationship with Amgen. This collaboration leverages the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and preclinical development, combining these strengths with Amgen, the world's largest research driven Biotech company, to deliver cost-effective new products that will help patients around the world. This partnership continues to demonstrate Jubilant's strategy to be India's largest innovation driven integrated pharmaceutical service provider supporting the global pharmaceutical Industry."

About Jubilant Biosys

Jubilant Biosys Ltd.(www.jubilantbiosys.com) is a subsidiary of Jubilant Organosys Ltd., that provides integrated Drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore, spread over an area of approximately 125,000 sq. ft. The Center houses over 500 scientists specializing in multi-disciplines including biology, chemistry, structural biology, pharmacology, molecular modeling, crystallography and information technology, collaborating with global pharma companies in USA, Europe and Japan.

About Jubilant

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products ,exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile Injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquids) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services ,generic dosage forms and Health Care.

Jubilant Organosys has geographically diversified manufacturing facilities at ten locations: Gajraula (UP), Nanjangud (Karnataka), Roorkee (Uttarakhand), Nira (Maharashtra), Udaipur (Rajasthan), Samlaya (Gujarat), Ambarnath (Mumbai), Salisbury, state of Maryland (USA), Spokane, state of Washington (USA) and Kirkland, state of Quebec (Canada). Together, these help Jubilant cater to 150 customers across more than 50 countries around the world.

For further information please contact:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Back